Lucid Diagnostics Inc. (LUCD)
After hours:
| Previous Close | 0.8500 |
| Open | 0.8400 |
| Bid | 0.8281 x 100 |
| Ask | 0.9148 x 100 |
| Day's Range | 0.8300 - 0.8800 |
| 52 Week Range | 0.6300 - 1.7210 |
| Volume | |
| Avg. Volume | 178,518 |
| Market Cap | 45.788M |
| Beta (5Y Monthly) | 1.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2600 |
| Earnings Date | May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
PR NewswireLucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it performed a record number of commercial EsoGuard® Esophageal DNA tests in the second quarter of 2024. The 3,174 tests represent a 31% increase sequentially from the first quarter.
- PR Newswire
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the launch of its newly redesigned corporate website, www.luciddx.com.
ZacksLucid Diagnostics (LUCD) Reports Positive ESOGUARD BE-1 Data
Lucid Diagnostic's (LUCD) ESOGUARD BE-1 study data shows high sensitivity and negative predictive value for the EsoGuard test, enhancing early detection of esophageal precancer in a screening population.
